WebBioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For three decades, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global … WebApr 21, 2013 · BioCentury This Week features:Janet Woodcock, Director, FDA Center For Drug Evaluation & ResearchKiran Mazumdar-Shaw, Chairman & Managing Director of Biocon ...
Articles by Steve Usdin’s Profile BioCentury, BioCentury This Week ...
Web3:43 PM Sep 13, 2024 Print PDF Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million.Sanofi (Euronext:SAN; NYSE:SNY), Zealand’s partner since 2003, … WebJan 24, 2024 · BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma … twcm australind
The Long Run with Luke Timmerman on Apple Podcasts
WebMay 2, 2024 · BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business … WebCheck out this great listen on Audible.com. The ruling on abortion drug mifepristone issued Friday by Texas District Judge Matthew Kacsmaryk could destabilize drug regulation, opening up every FDA approval to second guessing by any court in the U.S., Washington Editor Steve Usdin said on the lates... WebSep 26, 2024 · BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma … twc meble